Lund Melanoma Study Group
81 – 90 of 225
- show: 10
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=" "
width=" "
height=" "
allowtransparency="true"
frameborder="0">
</iframe>
- 2020
-
Mark
Effect of delay between nuclear medicine scanning and sentinel node biopsy on outcome in patients with cutaneous melanoma
(
- Contribution to journal › Article
-
Mark
Desloratadine and loratadine use associated with improved melanoma survival
(
- Contribution to journal › Letter
-
Mark
The Role of PTEN Loss in Immune Escape, Melanoma Prognosis and Therapy Response
(
- Contribution to journal › Article
-
Mark
Protein Expression in Metastatic Melanoma and the Link to Disease Presentation in a Range of Tumor Phenotypes
(
- Contribution to journal › Scientific review
-
Mark
Genome-wide association meta-analyses combining multiple risk phenotypes provide insights into the genetic architecture of cutaneous melanoma susceptibility
(
- Contribution to journal › Article
-
Mark
Long-term outcome of pT1a–b, cN0 breast cancer without axillary dissection or staging : a prospective observational study of 1543 women
(
- Contribution to journal › Article
-
Mark
Desloratadine and loratadine stand out among common H1-antihistamines for association with improved breast cancer survival
(
- Contribution to journal › Article
-
Mark
CYP27A1 expression is associated with risk of late lethal estrogen receptor-positive breast cancer in postmenopausal patients
(
- Contribution to journal › Article
-
Mark
Comment on "factors affecting sentinel node metastasis in thin (T1) cutaneous melanomas : Development and external validation of a predictive nomogram"
(
- Contribution to journal › Letter
-
Mark
TRIM study protocol - a prospective randomized multicenter Trial to assess the Role of Imaging during follow-up after radical surgery of stage IIB-C and III cutaneous malignant Melanoma
(
- Contribution to journal › Article